MersV1, PascalFrancis, Corpus, bibRecord, 000069

Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B

Identifieur interne : 000069 ( PascalFrancis/Corpus ); précédent : 000068; suivant : 000070

Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B

Auteurs : Aziz Alami Chentoufi ; Nicholas R. Binder ; Noureddine Berka ; Guillaume Durand ; Alex Nguyen ; Ilham Bettahi ; Bernard Maillere ; Lbachir Benmohamed

Source :

Journal of virology [ 0022-538X ] ; 2008.

RBID : Pascal:09-0013229

Descripteurs français

Pascal (Inist)
- Homme, Herpesvirus hominis, Asymptomatique, Lymphocyte T, Lymphocyte T cytotoxique, Déterminant antigénique, Glycoprotéine, Virologie, Antigène CD4.

English descriptors

KwdEn :
- Antigenic determinant, Asymptomatic, Cytotoxic T lymphocyte, Glycoprotein, Herpesvirus hominis, Human, T-Lymphocyte, Virology.

Abstract

The identification of "asymptomatic" (i.e., protective) epitopes recognized by T cells from herpes simplex virus (HSV)-seropositive healthy individuals is a prerequisite for an effective vaccine. Using the PepScan epitope mapping strategy, a library of 179 potential peptide epitopes (15-mers overlapping by 10 amino acids) was identified from HSV type 1 (HSV-1) glycoprotein B (gB), an antigen that induces protective immunity in both animal models and humans. Eighteen groups (G1 to G18) of 10 adjacent peptides each were first screened for T-cell antigenicity in 38 HSV-1-seropositive but HSV-2-seronegative individuals. Individual peptides within the two immunodominant groups (i.e., G4 and G14) were further screened with T cells from HLA-DR-genotyped and clinically defined symptomatic (n = 10) and asymptomatic (n = 10) HSV-1-seropositive healthy individuals. Peptides gB_161-175 and gB_166-180 within G4 and gB_661-675 within G14 recalled the strongest HLA-DR-dependent CD4⁺ T-cell proliferation and gamma interferon production. gB_166-180, gB_661-675, and gB_666-680 elicited ex vivo CD4⁺ cytotoxic T cells (CTLs) that lysed autologous HSV-1- and vaccinia virus (expressing gB)-infected lymphoblastoid cell lines. Interestingly, gB_166-180 and gB_666-680 peptide epitopes were strongly recognized by CD4⁺ T cells from 10 of 10 asymptomatic patients but not by CD4⁺ T cells from 10 of 10 symptomatic patients (P < 0.0001; analysis of variance posttest). Inversely, CD4⁺ T cells from symptomatic patients preferentially recognized gB_661-675 (P < 0.0001). Thus, we identified three previously unrecognized CD4⁺ CTL peptide epitopes in HSV-1 gB. Among these, gB_166-180 and gB_666-680 appear to be "asymptomatic" peptide epitopes and therefore should be considered in the design of future herpes vaccines.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-538X`
A03		`1`		`@0 J. virol.`
A05				`@2 82`
A06				`@2 23`
A08	`01`	`1`	`ENG`	`@1 Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B`
A11	`01`	`1`		`@1 ALAMI CHENTOUFI (Aziz)`
A11	`02`	`1`		`@1 BINDER (Nicholas R.)`
A11	`03`	`1`		`@1 BERKA (Noureddine)`
A11	`04`	`1`		`@1 DURAND (Guillaume)`
A11	`05`	`1`		`@1 NGUYEN (Alex)`
A11	`06`	`1`		`@1 BETTAHI (Ilham)`
A11	`07`	`1`		`@1 MAILLERE (Bernard)`
A11	`08`	`1`		`@1 BENMOHAMED (Lbachir)`
A14	`01`			`@1 Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine @2 Irvine, California 92697-4375 @3 USA @Z 1 aut. @Z 2 aut. @Z 5 aut. @Z 6 aut. @Z 8 aut.`
A14	`02`			`@1 Tissue Typing Laboratory @2 Calgary, Alberta T2L2K8 @3 CAN @Z 3 aut.`
A14	`03`			`@1 CEA, iBiTecS, Service d'Ingenierie Moléculaire des Protéines (SIMOPRO) @2 Gif Sur Yvette 91191 @3 FRA @Z 4 aut. @Z 7 aut.`
A14	`04`			`@1 Center for Immunology, University of California Irvine @2 Irvine, California 92697-1450 @3 USA @Z 8 aut.`
A20				`@1 11792-11802`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13592 @5 354000184531680310`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 80 ref.`
A47	`01`	`1`		`@0 09-0013229`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of virology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The identification of "asymptomatic" (i.e., protective) epitopes recognized by T cells from herpes simplex virus (HSV)-seropositive healthy individuals is a prerequisite for an effective vaccine. Using the PepScan epitope mapping strategy, a library of 179 potential peptide epitopes (15-mers overlapping by 10 amino acids) was identified from HSV type 1 (HSV-1) glycoprotein B (gB), an antigen that induces protective immunity in both animal models and humans. Eighteen groups (G1 to G18) of 10 adjacent peptides each were first screened for T-cell antigenicity in 38 HSV-1-seropositive but HSV-2-seronegative individuals. Individual peptides within the two immunodominant groups (i.e., G4 and G14) were further screened with T cells from HLA-DR-genotyped and clinically defined symptomatic (n = 10) and asymptomatic (n = 10) HSV-1-seropositive healthy individuals. Peptides gB_161-175 and gB_166-180 within G4 and gB_661-675 within G14 recalled the strongest HLA-DR-dependent CD4⁺ T-cell proliferation and gamma interferon production. gB_166-180, gB_661-675, and gB_666-680 elicited ex vivo CD4⁺ cytotoxic T cells (CTLs) that lysed autologous HSV-1- and vaccinia virus (expressing gB)-infected lymphoblastoid cell lines. Interestingly, gB_166-180 and gB_666-680 peptide epitopes were strongly recognized by CD4⁺ T cells from 10 of 10 asymptomatic patients but not by CD4⁺ T cells from 10 of 10 symptomatic patients (P < 0.0001; analysis of variance posttest). Inversely, CD4⁺ T cells from symptomatic patients preferentially recognized gB_661-675 (P < 0.0001). Thus, we identified three previously unrecognized CD4⁺ CTL peptide epitopes in HSV-1 gB. Among these, gB_166-180 and gB_666-680 appear to be "asymptomatic" peptide epitopes and therefore should be considered in the design of future herpes vaccines.
C02	`01`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Homme @5 01`
C03	`01`	`X`	`ENG`	`@0 Human @5 01`
C03	`01`	`X`	`SPA`	`@0 Hombre @5 01`
C03	`02`	`X`	`FRE`	`@0 Herpesvirus hominis @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Herpesvirus hominis @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Herpesvirus hominis @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Asymptomatique @5 05`
C03	`03`	`X`	`ENG`	`@0 Asymptomatic @5 05`
C03	`03`	`X`	`SPA`	`@0 Asintomático @5 05`
C03	`04`	`X`	`FRE`	`@0 Lymphocyte T @5 06`
C03	`04`	`X`	`ENG`	`@0 T-Lymphocyte @5 06`
C03	`04`	`X`	`SPA`	`@0 Linfocito T @5 06`
C03	`05`	`X`	`FRE`	`@0 Lymphocyte T cytotoxique @5 07`
C03	`05`	`X`	`ENG`	`@0 Cytotoxic T lymphocyte @5 07`
C03	`05`	`X`	`SPA`	`@0 Linfocito T citotóxico @5 07`
C03	`06`	`X`	`FRE`	`@0 Déterminant antigénique @5 08`
C03	`06`	`X`	`ENG`	`@0 Antigenic determinant @5 08`
C03	`06`	`X`	`SPA`	`@0 Determinante antigénico @5 08`
C03	`07`	`X`	`FRE`	`@0 Glycoprotéine @5 09`
C03	`07`	`X`	`ENG`	`@0 Glycoprotein @5 09`
C03	`07`	`X`	`SPA`	`@0 Glicoproteína @5 09`
C03	`08`	`X`	`FRE`	`@0 Virologie @5 10`
C03	`08`	`X`	`ENG`	`@0 Virology @5 10`
C03	`08`	`X`	`SPA`	`@0 Virología @5 10`
C03	`09`	`X`	`FRE`	`@0 Antigène CD4 @4 INC @5 79`
C07	`01`	`X`	`FRE`	`@0 Alphaherpesvirinae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Alphaherpesvirinae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Alphaherpesvirinae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Herpesviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Herpesviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Herpesviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
N21				`@1 007`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0013229 INIST
ET :	Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B
AU :	ALAMI CHENTOUFI (Aziz); BINDER (Nicholas R.); BERKA (Noureddine); DURAND (Guillaume); NGUYEN (Alex); BETTAHI (Ilham); MAILLERE (Bernard); BENMOHAMED (Lbachir)
AF :	Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine/Irvine, California 92697-4375/Etats-Unis (1 aut., 2 aut., 5 aut., 6 aut., 8 aut.); Tissue Typing Laboratory/Calgary, Alberta T2L2K8/Canada (3 aut.); CEA, iBiTecS, Service d'Ingenierie Moléculaire des Protéines (SIMOPRO)/Gif Sur Yvette 91191/France (4 aut., 7 aut.); Center for Immunology, University of California Irvine/Irvine, California 92697-1450/Etats-Unis (8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2008; Vol. 82; No. 23; Pp. 11792-11802; Bibl. 80 ref.
LA :	Anglais
EA :	The identification of "asymptomatic" (i.e., protective) epitopes recognized by T cells from herpes simplex virus (HSV)-seropositive healthy individuals is a prerequisite for an effective vaccine. Using the PepScan epitope mapping strategy, a library of 179 potential peptide epitopes (15-mers overlapping by 10 amino acids) was identified from HSV type 1 (HSV-1) glycoprotein B (gB), an antigen that induces protective immunity in both animal models and humans. Eighteen groups (G1 to G18) of 10 adjacent peptides each were first screened for T-cell antigenicity in 38 HSV-1-seropositive but HSV-2-seronegative individuals. Individual peptides within the two immunodominant groups (i.e., G4 and G14) were further screened with T cells from HLA-DR-genotyped and clinically defined symptomatic (n = 10) and asymptomatic (n = 10) HSV-1-seropositive healthy individuals. Peptides gB_161-175 and gB_166-180 within G4 and gB_661-675 within G14 recalled the strongest HLA-DR-dependent CD4⁺ T-cell proliferation and gamma interferon production. gB_166-180, gB_661-675, and gB_666-680 elicited ex vivo CD4⁺ cytotoxic T cells (CTLs) that lysed autologous HSV-1- and vaccinia virus (expressing gB)-infected lymphoblastoid cell lines. Interestingly, gB_166-180 and gB_666-680 peptide epitopes were strongly recognized by CD4⁺ T cells from 10 of 10 asymptomatic patients but not by CD4⁺ T cells from 10 of 10 symptomatic patients (P < 0.0001; analysis of variance posttest). Inversely, CD4⁺ T cells from symptomatic patients preferentially recognized gB_661-675 (P < 0.0001). Thus, we identified three previously unrecognized CD4⁺ CTL peptide epitopes in HSV-1 gB. Among these, gB_166-180 and gB_666-680 appear to be "asymptomatic" peptide epitopes and therefore should be considered in the design of future herpes vaccines.
CC :	002A05C10
FD :	Homme; Herpesvirus hominis; Asymptomatique; Lymphocyte T; Lymphocyte T cytotoxique; Déterminant antigénique; Glycoprotéine; Virologie; Antigène CD4
FG :	Alphaherpesvirinae; Herpesviridae; Virus
ED :	Human; Herpesvirus hominis; Asymptomatic; T-Lymphocyte; Cytotoxic T lymphocyte; Antigenic determinant; Glycoprotein; Virology
EG :	Alphaherpesvirinae; Herpesviridae; Virus
SD :	Hombre; Herpesvirus hominis; Asintomático; Linfocito T; Linfocito T citotóxico; Determinante antigénico; Glicoproteína; Virología
LO :	INIST-13592.354000184531680310
ID :	09-0013229

Links to Exploration step

Pascal:09-0013229

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B</title>
<author><name sortKey="Alami Chentoufi, Aziz" sort="Alami Chentoufi, Aziz" uniqKey="Alami Chentoufi A" first="Aziz" last="Alami Chentoufi">Aziz Alami Chentoufi</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Binder, Nicholas R" sort="Binder, Nicholas R" uniqKey="Binder N" first="Nicholas R." last="Binder">Nicholas R. Binder</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berka, Noureddine" sort="Berka, Noureddine" uniqKey="Berka N" first="Noureddine" last="Berka">Noureddine Berka</name>
<affiliation><inist:fA14 i1="02"><s1>Tissue Typing Laboratory</s1>
<s2>Calgary, Alberta T2L2K8</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durand, Guillaume" sort="Durand, Guillaume" uniqKey="Durand G" first="Guillaume" last="Durand">Guillaume Durand</name>
<affiliation><inist:fA14 i1="03"><s1>CEA, iBiTecS, Service d'Ingenierie Moléculaire des Protéines (SIMOPRO)</s1>
<s2>Gif Sur Yvette 91191</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nguyen, Alex" sort="Nguyen, Alex" uniqKey="Nguyen A" first="Alex" last="Nguyen">Alex Nguyen</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bettahi, Ilham" sort="Bettahi, Ilham" uniqKey="Bettahi I" first="Ilham" last="Bettahi">Ilham Bettahi</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maillere, Bernard" sort="Maillere, Bernard" uniqKey="Maillere B" first="Bernard" last="Maillere">Bernard Maillere</name>
<affiliation><inist:fA14 i1="03"><s1>CEA, iBiTecS, Service d'Ingenierie Moléculaire des Protéines (SIMOPRO)</s1>
<s2>Gif Sur Yvette 91191</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Benmohamed, Lbachir" sort="Benmohamed, Lbachir" uniqKey="Benmohamed L" first="Lbachir" last="Benmohamed">Lbachir Benmohamed</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Center for Immunology, University of California Irvine</s1>
<s2>Irvine, California 92697-1450</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0013229</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 09-0013229 INIST</idno>
<idno type="RBID">Pascal:09-0013229</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000069</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B</title>
<author><name sortKey="Alami Chentoufi, Aziz" sort="Alami Chentoufi, Aziz" uniqKey="Alami Chentoufi A" first="Aziz" last="Alami Chentoufi">Aziz Alami Chentoufi</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Binder, Nicholas R" sort="Binder, Nicholas R" uniqKey="Binder N" first="Nicholas R." last="Binder">Nicholas R. Binder</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berka, Noureddine" sort="Berka, Noureddine" uniqKey="Berka N" first="Noureddine" last="Berka">Noureddine Berka</name>
<affiliation><inist:fA14 i1="02"><s1>Tissue Typing Laboratory</s1>
<s2>Calgary, Alberta T2L2K8</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durand, Guillaume" sort="Durand, Guillaume" uniqKey="Durand G" first="Guillaume" last="Durand">Guillaume Durand</name>
<affiliation><inist:fA14 i1="03"><s1>CEA, iBiTecS, Service d'Ingenierie Moléculaire des Protéines (SIMOPRO)</s1>
<s2>Gif Sur Yvette 91191</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nguyen, Alex" sort="Nguyen, Alex" uniqKey="Nguyen A" first="Alex" last="Nguyen">Alex Nguyen</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bettahi, Ilham" sort="Bettahi, Ilham" uniqKey="Bettahi I" first="Ilham" last="Bettahi">Ilham Bettahi</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maillere, Bernard" sort="Maillere, Bernard" uniqKey="Maillere B" first="Bernard" last="Maillere">Bernard Maillere</name>
<affiliation><inist:fA14 i1="03"><s1>CEA, iBiTecS, Service d'Ingenierie Moléculaire des Protéines (SIMOPRO)</s1>
<s2>Gif Sur Yvette 91191</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Benmohamed, Lbachir" sort="Benmohamed, Lbachir" uniqKey="Benmohamed L" first="Lbachir" last="Benmohamed">Lbachir Benmohamed</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Center for Immunology, University of California Irvine</s1>
<s2>Irvine, California 92697-1450</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigenic determinant</term>
<term>Asymptomatic</term>
<term>Cytotoxic T lymphocyte</term>
<term>Glycoprotein</term>
<term>Herpesvirus hominis</term>
<term>Human</term>
<term>T-Lymphocyte</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme</term>
<term>Herpesvirus hominis</term>
<term>Asymptomatique</term>
<term>Lymphocyte T</term>
<term>Lymphocyte T cytotoxique</term>
<term>Déterminant antigénique</term>
<term>Glycoprotéine</term>
<term>Virologie</term>
<term>Antigène CD4</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The identification of "asymptomatic" (i.e., protective) epitopes recognized by T cells from herpes simplex virus (HSV)-seropositive healthy individuals is a prerequisite for an effective vaccine. Using the PepScan epitope mapping strategy, a library of 179 potential peptide epitopes (15-mers overlapping by 10 amino acids) was identified from HSV type 1 (HSV-1) glycoprotein B (gB), an antigen that induces protective immunity in both animal models and humans. Eighteen groups (G1 to G18) of 10 adjacent peptides each were first screened for T-cell antigenicity in 38 HSV-1-seropositive but HSV-2-seronegative individuals. Individual peptides within the two immunodominant groups (i.e., G4 and G14) were further screened with T cells from HLA-DR-genotyped and clinically defined symptomatic (n = 10) and asymptomatic (n = 10) HSV-1-seropositive healthy individuals. Peptides gB<sub>161-175</sub>
 and gB<sub>166-180</sub>
 within G4 and gB<sub>661-675</sub>
 within G14 recalled the strongest HLA-DR-dependent CD4<sup>+</sup>
 T-cell proliferation and gamma interferon production. gB<sub>166-180,</sub>
 gB<sub>661-675</sub>
, and gB<sub>666-680</sub>
 elicited ex vivo CD4<sup>+</sup>
 cytotoxic T cells (CTLs) that lysed autologous HSV-1- and vaccinia virus (expressing gB)-infected lymphoblastoid cell lines. Interestingly, gB<sub>166-180</sub>
 and gB<sub>666-680</sub>
 peptide epitopes were strongly recognized by CD4<sup>+</sup>
 T cells from 10 of 10 asymptomatic patients but not by CD4<sup>+</sup>
 T cells from 10 of 10 symptomatic patients (P < 0.0001; analysis of variance posttest). Inversely, CD4<sup>+</sup>
 T cells from symptomatic patients preferentially recognized gB<sub>661-675</sub>
 (P < 0.0001). Thus, we identified three previously unrecognized CD4<sup>+</sup>
 CTL peptide epitopes in HSV-1 gB. Among these, gB<sub>166-180</sub>
 and gB<sub>666-680</sub>
 appear to be "asymptomatic" peptide epitopes and therefore should be considered in the design of future herpes vaccines.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-538X</s0>
</fA01>
<fA03 i2="1"><s0>J. virol.</s0>
</fA03>
<fA05><s2>82</s2>
</fA05>
<fA06><s2>23</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ALAMI CHENTOUFI (Aziz)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BINDER (Nicholas R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BERKA (Noureddine)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DURAND (Guillaume)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>NGUYEN (Alex)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BETTAHI (Ilham)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MAILLERE (Bernard)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BENMOHAMED (Lbachir)</s1>
</fA11>
<fA14 i1="01"><s1>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine</s1>
<s2>Irvine, California 92697-4375</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Tissue Typing Laboratory</s1>
<s2>Calgary, Alberta T2L2K8</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>CEA, iBiTecS, Service d'Ingenierie Moléculaire des Protéines (SIMOPRO)</s1>
<s2>Gif Sur Yvette 91191</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Center for Immunology, University of California Irvine</s1>
<s2>Irvine, California 92697-1450</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>11792-11802</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13592</s2>
<s5>354000184531680310</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>80 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0013229</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The identification of "asymptomatic" (i.e., protective) epitopes recognized by T cells from herpes simplex virus (HSV)-seropositive healthy individuals is a prerequisite for an effective vaccine. Using the PepScan epitope mapping strategy, a library of 179 potential peptide epitopes (15-mers overlapping by 10 amino acids) was identified from HSV type 1 (HSV-1) glycoprotein B (gB), an antigen that induces protective immunity in both animal models and humans. Eighteen groups (G1 to G18) of 10 adjacent peptides each were first screened for T-cell antigenicity in 38 HSV-1-seropositive but HSV-2-seronegative individuals. Individual peptides within the two immunodominant groups (i.e., G4 and G14) were further screened with T cells from HLA-DR-genotyped and clinically defined symptomatic (n = 10) and asymptomatic (n = 10) HSV-1-seropositive healthy individuals. Peptides gB<sub>161-175</sub>
 and gB<sub>166-180</sub>
 within G4 and gB<sub>661-675</sub>
 within G14 recalled the strongest HLA-DR-dependent CD4<sup>+</sup>
 T-cell proliferation and gamma interferon production. gB<sub>166-180,</sub>
 gB<sub>661-675</sub>
, and gB<sub>666-680</sub>
 elicited ex vivo CD4<sup>+</sup>
 cytotoxic T cells (CTLs) that lysed autologous HSV-1- and vaccinia virus (expressing gB)-infected lymphoblastoid cell lines. Interestingly, gB<sub>166-180</sub>
 and gB<sub>666-680</sub>
 peptide epitopes were strongly recognized by CD4<sup>+</sup>
 T cells from 10 of 10 asymptomatic patients but not by CD4<sup>+</sup>
 T cells from 10 of 10 symptomatic patients (P < 0.0001; analysis of variance posttest). Inversely, CD4<sup>+</sup>
 T cells from symptomatic patients preferentially recognized gB<sub>661-675</sub>
 (P < 0.0001). Thus, we identified three previously unrecognized CD4<sup>+</sup>
 CTL peptide epitopes in HSV-1 gB. Among these, gB<sub>166-180</sub>
 and gB<sub>666-680</sub>
 appear to be "asymptomatic" peptide epitopes and therefore should be considered in the design of future herpes vaccines.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Homme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Human</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Herpesvirus hominis</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Herpesvirus hominis</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Herpesvirus hominis</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Asymptomatique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Asymptomatic</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Asintomático</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lymphocyte T</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>T-Lymphocyte</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Linfocito T</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lymphocyte T cytotoxique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cytotoxic T lymphocyte</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Linfocito T citotóxico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Déterminant antigénique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antigenic determinant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Determinante antigénico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Glycoprotéine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Glycoprotein</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Glicoproteína</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Virologie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Virology</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Virología</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antigène CD4</s0>
<s4>INC</s4>
<s5>79</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Alphaherpesvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Alphaherpesvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Alphaherpesvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Herpesviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Herpesviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Herpesviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>007</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0013229 INIST</NO>
<ET>Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B</ET>
<AU>ALAMI CHENTOUFI (Aziz); BINDER (Nicholas R.); BERKA (Noureddine); DURAND (Guillaume); NGUYEN (Alex); BETTAHI (Ilham); MAILLERE (Bernard); BENMOHAMED (Lbachir)</AU>
<AF>Laboratory of Cellular and Molecular Immunology, The Gavin S. Herbert Eye Institute, University of California Irvine, School of Medicine/Irvine, California 92697-4375/Etats-Unis (1 aut., 2 aut., 5 aut., 6 aut., 8 aut.); Tissue Typing Laboratory/Calgary, Alberta T2L2K8/Canada (3 aut.); CEA, iBiTecS, Service d'Ingenierie Moléculaire des Protéines (SIMOPRO)/Gif Sur Yvette 91191/France (4 aut., 7 aut.); Center for Immunology, University of California Irvine/Irvine, California 92697-1450/Etats-Unis (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2008; Vol. 82; No. 23; Pp. 11792-11802; Bibl. 80 ref.</SO>
<LA>Anglais</LA>
<EA>The identification of "asymptomatic" (i.e., protective) epitopes recognized by T cells from herpes simplex virus (HSV)-seropositive healthy individuals is a prerequisite for an effective vaccine. Using the PepScan epitope mapping strategy, a library of 179 potential peptide epitopes (15-mers overlapping by 10 amino acids) was identified from HSV type 1 (HSV-1) glycoprotein B (gB), an antigen that induces protective immunity in both animal models and humans. Eighteen groups (G1 to G18) of 10 adjacent peptides each were first screened for T-cell antigenicity in 38 HSV-1-seropositive but HSV-2-seronegative individuals. Individual peptides within the two immunodominant groups (i.e., G4 and G14) were further screened with T cells from HLA-DR-genotyped and clinically defined symptomatic (n = 10) and asymptomatic (n = 10) HSV-1-seropositive healthy individuals. Peptides gB<sub>161-175</sub>
 and gB<sub>166-180</sub>
 within G4 and gB<sub>661-675</sub>
 within G14 recalled the strongest HLA-DR-dependent CD4<sup>+</sup>
 T-cell proliferation and gamma interferon production. gB<sub>166-180,</sub>
 gB<sub>661-675</sub>
, and gB<sub>666-680</sub>
 elicited ex vivo CD4<sup>+</sup>
 cytotoxic T cells (CTLs) that lysed autologous HSV-1- and vaccinia virus (expressing gB)-infected lymphoblastoid cell lines. Interestingly, gB<sub>166-180</sub>
 and gB<sub>666-680</sub>
 peptide epitopes were strongly recognized by CD4<sup>+</sup>
 T cells from 10 of 10 asymptomatic patients but not by CD4<sup>+</sup>
 T cells from 10 of 10 symptomatic patients (P < 0.0001; analysis of variance posttest). Inversely, CD4<sup>+</sup>
 T cells from symptomatic patients preferentially recognized gB<sub>661-675</sub>
 (P < 0.0001). Thus, we identified three previously unrecognized CD4<sup>+</sup>
 CTL peptide epitopes in HSV-1 gB. Among these, gB<sub>166-180</sub>
 and gB<sub>666-680</sub>
 appear to be "asymptomatic" peptide epitopes and therefore should be considered in the design of future herpes vaccines.</EA>
<CC>002A05C10</CC>
<FD>Homme; Herpesvirus hominis; Asymptomatique; Lymphocyte T; Lymphocyte T cytotoxique; Déterminant antigénique; Glycoprotéine; Virologie; Antigène CD4</FD>
<FG>Alphaherpesvirinae; Herpesviridae; Virus</FG>
<ED>Human; Herpesvirus hominis; Asymptomatic; T-Lymphocyte; Cytotoxic T lymphocyte; Antigenic determinant; Glycoprotein; Virology</ED>
<EG>Alphaherpesvirinae; Herpesviridae; Virus</EG>
<SD>Hombre; Herpesvirus hominis; Asintomático; Linfocito T; Linfocito T citotóxico; Determinante antigénico; Glicoproteína; Virología</SD>
<LO>INIST-13592.354000184531680310</LO>
<ID>09-0013229</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000069 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000069 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0013229
   |texte=   Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B

Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri